Skip to content
DataLookout
Menu

NCT07022483

A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion moved earlier from Mar 23, 2032 to Feb 26, 2030 Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria shortened, about 8 words
    • Trial sites expanded: 75 → 86 locations
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study title expanded, about 4 words
  2. Minor Trial sites expanded: 61 → 75 locationsv7
  3. Minor Trial sites expanded: 40 → 61 locationsv6
  4. Minor Study sites: 17 to 40v5
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 17
    • Start date changed from estimate of Oct 31, 2025 to Sep 30, 2025
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Eligibility criteria expanded, about 22 wordsv3
  2. Notable Start date: Aug 25, 2025 to Oct 31, 2025v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review or by Histopathologic Confirmation of Disease Recurrence per Local Assessment
Timeframe: From randomization to the first documented local regional recurrence, distant metastasis, or death due to any cause, whichever occurs first, up to approximately 51 months

Secondary (1)

Overall Survival

Arms and interventions

Arm A: T-DXdExperimental

Participants will receive T-DXd 5.4 mg/kg intravenously (IV) once every 3 weeks (Q3W) with or without \[optional\] radiotherapy

Arm B: Standard of Care ChemotherapyActive comparator

Participants will receive carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W, or AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W with or without \[optional\] radiotherapy or chemoradiotherapy (EBRT plus cisplatin \[as radiosensitizer\] 50 mg/m2

Drugs: Trastuzumab Deruxtecan, Chemotherapy

Sites

86 sites in 15 countries

China 16, Japan 15, United States 14, Italy 7, Argentina 6, Spain 6, Poland 4, Taiwan 4, Chile 3, France 3, South Korea 3, Germany 2, Greece 1, Israel 1, Portugal 1